This month, we're diving in deep on the U.S. approval of lenacapavir for PrEP -- both the promise it offers in expanding HIV prevention options and the current uncertainty around access, both in the U.S. and abroad. We also discuss growing concern within the HIV clinical community that our gold-standard guidelines for HIV treatment, care, and prevention may be rousted loose from their long-standing home within the Office of AIDS Research at the U.S. National Institutes of Health. And Laura Waters shares what she's most eager to learn about at IAS 2025, the global HIV science meeting that is taking place as this episode drops.

 

Please support our podcast by visiting the transcript, which includes links to the many references we mention in this episode: https://www.thebodypro.com/podcast/hiv/future-hiv-care-lenacapavir-prep-guidelines-july-2025

 

The podfolx: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

This month, we're digging into some recent, clinically notable HIV research in the U.S. that leaves us seeing a complex mix of clouds and silver (or perhaps gold?) linings. Specifically: new findings on ART prescription practices; a study on barriers to rapid HIV treatment initiation; and state-level data on PrEP prescribing trends relative to HIV diagnoses.

 

Support us by visiting the online transcript: https://www.thebodypro.com/podcast/hiv/future-hiv-care-clouds-silver-linings-june-2025

 

And watch this touching video from Oslo Pride on the importance of symbols: https://www.youtube.com/watch?v=UVepoXddTW4

 

The pod production team: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

In a time of growing uncertainty for the HIV response within the U.S., you may be wondering: What do I do if the public guidelines and resources I rely on to provide HIV-related clinical services cease receiving updates or are permanently removed? Laura and Myles discuss the complexities of our current moment -- and the extent to which our colleagues across the pond in the British HIV Association (BHIVA) can help fill the gap. Laura will also review recent highlights from BHIVA's annual Spring Conference, a cross-disciplinary meeting featuring clinical research and state-of-the-art updates.

°

Read the full transcript, which includes a bevy of relevant links: https://www.thebodypro.com/podcast/hiv/future-hiv-care-bhiva-may-2025

°

The pod production team: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

Myles Helfand and Laura Waters, M.D., FRCP, discuss recently published, clinically noteworthy findings from a trio of venerable HIV cohort studies. First, they review new data from the ATHENA study on non-AIDS events among so-called "HIV controllers." They then move on to recent findings from the START study regarding the link between ART initiation timing and cardiovascular disease risk. Finally, they explore new REPRIEVE data exploring the impact (or lack thereof) of statin use on non-cardiovascular events.

¶

Read (and share!) the full transcript: https://www.thebodypro.com/hiv/future-hiv-care-nuances-matter-april-2025

¶

The pod production team: Our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

Laura Waters, M.D., and Myles Helfand recap several noteworthy moments and clinically important studies from this year's Conference on Retroviruses and Opportunistic Infections (CROI 2025), which took place during a deeply uncertain moment in the HIV field, both domestically and globally. Their research conversation includes highlights in antiretroviral therapy strategies; comorbidities; emerging cure science; and prevention.¶

¶

 

Access the full transcript, which includes contextual links to study abstracts and other reference info: https://www.thebodypro.com/hiv/future-hiv-care-croi-2025¶

¶

The pod team: Our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

Myles Helfand is joined by new co-host and expert HIV clinician-researcher Laura Waters, M.D., to dig into an issue they had once hoped they would never need to spend a podcast episode discussing: The rapidly unfolding impact of a new Trump administration on both the global fight against HIV and efforts to combat the virus -- and provide care and services -- within the United States.¶ ¶ Full episode transcript and key resource links:  https://www.thebodypro.com/hiv/future-hiv-care-initial-trump-policy-impact¶   TheBodyPro's article on alternate sources of federal HIV data/info:¶  https://www.thebodypro.com/hiv/hiv-data-purge-2025-access-resources¶ ¶ The team: Our podcast hosts are Myles Helfand and Laura Waters, M.D.; our executive producer is Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; and our audio editor is Kim Buikema.

You can't truly look to the future without taking time to make sense of the past. That's why our January episode explores some of the most important studies and events of 2024 from an HIV clinical standpoint, and discusses what those highlights mean for HIV care moving forward.¶ ¶ The guest: David Alain Wohl, M.D., a professor of medicine in the Division of Infectious Diseases at the University of North Carolina and the co-principal investigator of UNC's Infectious Diseases Clinical Research Trials Unit.¶ ¶ The reference materials:¶ ¶ Episode transcript:  https://www.thebodypro.com/hiv/future-hiv-care-wohl-top-10-jan-2025¶ ¶ Wohl's 'Top 10 HIV Clinical Developments of 2024' series:¶  https://www.thebodypro.com/gallery/top-10-hiv-clinical-developments-2024¶ ¶ The team: Our executive producer is Myles Helfand; our project manager is Alina Mogollon-Volk; our audio producer is Alex Portaluppi; and our audio editor is Kim Buikema.

GLP-1 Agonists and HIV: Do Weight-Loss Drugs Make Sense for Your Patients?     Three GLP-1 agonist drugs (which originally had been confined to diabetes treatment) are currently FDA approved specifically for weight loss. The rapid uptake of these medications in the U.S. has naturally led to questions within the HIV clinical community about their safety and efficacy in people living with HIV, whose journeys with weight gain and weight loss overlap with the general population but also may differ significantly in a few key ways.   Joining us on the podcast this month to provide some answers is one of the most prominent clinician researchers exploring this topic today: Grace McComsey, M.D., a professor of pediatrics and medicine at Case Western Reserve University, as well as the vice president of research and the associate chief scientific officer at the University Hospitals Health System in Cleveland, Ohio.     Read the transcript: https://www.thebodypro.com/article/future-hiv-care-glp-1-agonists-semaglutide     Credits: Our executive producer is Myles Helfand; our project manager is Alina Mogollon-Volk; our audio producers/engineers are Alex Portaluppi and Lucy Mueller; and our series editors are Maria Elena Perez and Juan Michael Porter II. This episode's audio was edited by Kim Buikema.

For all too many people living with HIV in the U.S., the prospect of facing incarceration because of their status is not an abstraction: It is a real and present danger. And in many states, it has nothing to do with science. This month, Juan Michael Porter II speaks with Joseph Cherabie, M.D., M.Sc., about why it's so important for clinicians to educate themselves about HIV criminalization laws in their state -- and then work to support and empower their patients while pushing to get these laws removed.     Read the transcript, which includes valuable links to related resources: https://www.thebodypro.com/article/future-hiv-care-criminalization     Credits: Our executive producer is Myles Helfand; our project manager is Alina Mogollon-Volk; our audio producers/engineers are Alex Portaluppi and Lucy Mueller; and our series editors are Maria Elena Perez and Juan Michael Porter II. This episode's audio was edited by Kim Buikema.

Summer weather is transitioning into sweater weather in most of the U.S., and that means we -- and our patients -- are about to spend a lot more time indoors, inevitably getting exposed to numerous microbes. Accordingly, this month we're talking about vaccinations for people living with HIV: why they're critical, what to consider, how to discuss the topic with your patients, and how to help ensure people living with HIV equitably receive the care they deserve.     Our guests for this episode, which is hosted by Juan Michael Porter II, are Stella Safo, M.D., M.P.H., of Just Equity for Health and Perry Halkitis, Ph.D., M.P.H., of the Rutgers School of Public Health.     Read the transcript: https://www.thebodypro.com/article/future-hiv-care-podcast-vaccinations     Credits: Our executive producer is Myles Helfand; our project manager is Alina Mogollon-Volk; our audio producers/engineers are Alex Portaluppi and Lucy Mueller; and our series editors are Maria Elena Perez and Juan Michael Porter II. This episode's audio was edited by Kim Buikema.